These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 9781280)

  • 1. Whole-body [18F]FDG PET in the management of metastatic brain tumours.
    Kim DG; Kim CY; Paek SH; Lee DS; Chung JK; Jung HW; Cho BK
    Acta Neurochir (Wien); 1998; 140(7):665-73; discussion 673-4. PubMed ID: 9781280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of dissemination studies with FDG whole-body positron emission tomography in patients with suspected metastatic tumours of brain and spine.
    Go KG; Pruim J; Que TH; Vaalburg W; Haaxma-Reiche H
    Acta Neurochir (Wien); 2000; 142(6):627-31. PubMed ID: 10949436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors.
    Gupta NC; Nicholson P; Bloomfield SM
    Ann Surg; 1999 Aug; 230(2):202-6. PubMed ID: 10450734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of whole-body (18)F-FDG PET in patients with suspected metastatic brain tumors.
    Jeong HJ; Chung JK; Kim YK; Kim CY; Kim DG; Jeong JM; Lee DS; Jung HW; Lee MC
    J Nucl Med; 2002 Nov; 43(11):1432-7. PubMed ID: 12411544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
    Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA
    Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors.
    Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z
    Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis.
    Dietlein M; Krug B; Groth W; Smolarz K; Scheidhauer K; Psaras T; Stützer H; Lackner K; Schicha H
    Nucl Med Commun; 1999 Mar; 20(3):255-61. PubMed ID: 10093075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer.
    Lee HY; Chung JK; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
    Ann Nucl Med; 2008 May; 22(4):281-6. PubMed ID: 18535878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The usefulness of whole body FDG-PET/CT in patients with brain metastasis].
    Nakagawa K; Aoyagi M; Inaji M; Maehara T; Toriyama H; Kawano Y; Tamaki M; Nariai T; Ohno K
    No Shinkei Geka; 2009 Feb; 37(2):159-66. PubMed ID: 19227157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin.
    Kaya AO; Coskun U; Unlu M; Akdemir UO; Ozdemir NY; Zengin N; Benekli M; Yildiz R; Yaman E; Ozturk B; Gumus M; Uner A; Yamac D; Ucgul E; Buyukberber S
    Asian Pac J Cancer Prev; 2008; 9(4):683-6. PubMed ID: 19256759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
    Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
    Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
    Manohar K; Bhattacharya A; Mittal BR
    Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine.
    Pirotte B; Goldman S; David P; Wikler D; Damhaut P; Vandesteene A; Salmon L; Brotchi J; Levivier M
    Acta Neurochir Suppl; 1997; 68():133-8. PubMed ID: 9233429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy.
    Rohren EM; Provenzale JM; Barboriak DP; Coleman RE
    Radiology; 2003 Jan; 226(1):181-7. PubMed ID: 12511688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.